TY - JOUR AU - Marey, H. AU - Chai, A. AU - Bikov, András TI - Periodic limb movements in sleep in patients using antidepressants JF - SLEEP MEDICINE REVIEWS J2 - SLEEP MED REV VL - 79 PY - 2025 SN - 1087-0792 DO - 10.1016/j.smrv.2024.102011 UR - https://m2.mtmt.hu/api/publication/35425111 ID - 35425111 N1 - Export Date: 29 September 2024 CODEN: SMREF Correspondence Address: Bikov, A.; University of ManchesterUnited Kingdom; email: Andras.bikov@mft.nhs.uk LA - English DB - MTMT ER - TY - JOUR AU - Bagnasco, D. AU - Ansotegui, I. AU - Baiardini, I. AU - Benfante, A. AU - Bernstein, J.A. AU - Bikov, András AU - Bondi, B. AU - Boulet, L.P. AU - Panaitescu, C. AU - Canonica, G.W. AU - Chong-Neto, H. AU - Dubuske, L. AU - El-Owaidy, R. AU - Ferraris, M. AU - Filipovic, M. AU - Gonzalez-Barcala, F.J. AU - Guidos, Fogelbach G. AU - Ivancevich, J.C. AU - Jusufovic, E. AU - Kowal, K. AU - Lantieri, F. AU - Mahboub, B. AU - Mihaicuta, S. AU - Mincarini, M. AU - Nedeva, D. AU - Novakova, P. AU - Novakova, S. AU - Nunes, C. AU - Ricchiuto, F.R. AU - Santus, P. AU - Scichilone, N. AU - Steiropoulos, P. AU - Tiotiu, A. AU - Tomasello, A. AU - Virchow, J.C. AU - Yadav, R. AU - Zunino, S. AU - Braido, F. TI - Triple inhaled therapy in asthma: Beliefs, behaviours and doubts JF - PULMONARY PHARMACOLOGY & THERAPEUTICS J2 - PULM PHARMACOL THER VL - 87 PY - 2024 SN - 1094-5539 DO - 10.1016/j.pupt.2024.102333 UR - https://m2.mtmt.hu/api/publication/35626887 ID - 35626887 N1 - Respiratory Diseases and Allergy Department, IRCCS Polyclinic Hospital San Martino, Genoa, Italy Department of Internal Medicine (DiMI), University of Genoa, Italy Department of Allergy & Immunology, Hospital Quirónsalud Bizkaia, Bilbao, Spain Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy University of Cincinnati, Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Cincinnati, OH, United States Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Faculty of Medical and Human Sciences, Manchester, United Kingdom North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom Department of Medicine, Laval University, Quebec, QC, Canada Center of Immuno-Physiology and Biotechnologies, Department of Functional Sciences, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania OncoGen Center, Pius Brinzeu County Clinical Emergency Hospital, Timisoara, Romania Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy Serviço de Alergia e Imunologia, Complexo Hospital de Clinicas, Universidade Federal do Paraná, Curitiba, Brazil Department of Medicine, The George Washington University Hospital, Washington DC, United States Pediatric Allergy, Immunology, and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt Institute for Lung Diseases and Tuberculosis, Niš, Serbia Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Galicia, Spain Department of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain Department of Respiratory Medicine, University Hospital of Santiago de Compostela (CHUS), Santiago de Compostela, Spain Instituto de Investigación Sanitaria de Santiago de Compostela, Spain Department of Structural Biochemistry, SEPI/ENMH, I.P.N, México city, Mexico Department of Allergy and Immunology, Clínica Santa Isabel, Buenos Aires, Argentina Medical Faculty, University of Tuzla, Tuzla, Bosnia and Herzegovina Department of Allergology and Internal Medicine, and Department of Experimental Allergology and Immunology, Medical University of Bialystok, Bialystok, Poland Biostatistics Unit, Health Science Department, University of Genoa, Via Pastore 1, Genoa, 16132, Italy Rashid Hospital, Dubai, United Arab Emirates Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates Victor Babes Infectious Diseases and Pulmonology Clinical Hospital Timisoara, Timisoara, 300310, Romania Centre for Research and Innovation in Precision Medicine of Respiratory Diseases, Department of Pulmonology, “Victor Babes” University of Medicine and Pharmacy Timisoara, Timisoara, 300041, Romania Clinic of Asthma and Allergology, UMBAL Alexandrovska, Medical University Sofia, Sofia, Bulgaria Clinic of Clinical Allergy, Medical University Sofia, Sofia, Bulgaria Allergy Unit, Internal Consulting Department, University Hospital “St. George”, Plovdiv, Bulgaria Centro de ImmunoAlergologia de Algarve, Porto, Portugal Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy Section of Respiratory Diseases, L. Sacco University Hospital, ASST Fatebenefratelli-Sacco, Milan, Italy Department of Respiratory Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece Department of Pneumology, University Hospital Saint-Luc, University of Louvain, Brussels, Belgium Pole Pneumology, ENT and Dermatology-LUNS, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium Departments of Pneumology and Intensive Care Medicine, University of Rostock, Rostock, 18057, Germany Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India Hospital Italiano de Buenos Aires, Sección de Pulmonology, Buenos Aires, Argentina Export Date: 08 December 2024; Cited By: 0; Correspondence Address: M. Ferraris; Respiratory Diseases and Allergy Department, IRCCS Polyclinic Hospital San Martino, Genoa, Italy; email: s4200374@studenti.unige.it; CODEN: PPTHF AB - Long-acting muscarinic antagonists (LAMA) in association with inhaled corticosteroids (ICS) plus long-acting beta-2 agonists (LABA) are recommended by the GINA report as further option in step 4 and first choice in step 5 treatment. Despite consistent evidence of its efficacy and safety, inhaled triple therapy (ITT) is still not largely used in patients with asthma. With the aim to explore belief and behaviours of asthma specialists, an ad hoc survey has been developed by a panel of Interasma Scientific Network (INESnet) experts and subsequently defined by two Delphi rounds among an international group of physicians. The questionnaire has been distributed through Interasma social media between June and September 2023. Besides a descriptive analysis, to assess the responses gathered from the questionnaire, Spearman's non-parametric statistical method was employed. Totally, three hundred fourteen questionnaires were completed. Clinicians' attitudes and behaviours toward timing and methodologies adopted in prescribing ITT, were analysed. 35.7 % specialists consider ITT as a relevant therapeutic option, 61.8 % that is second option after reaching high dose of ICS-LABA and 89.2 % agreed that optimization of inhaled therapy should be attempted before the use of biological drugs. Persistent flow limitation and high reversibility are considered predictive factors of response. Specialists consider ITT a resource in asthma management. Although its efficacy in decreasing exacerbation rate and improving lung function were well known, the survey revealed persistent uncertainties among clinicians in positioning it highlighting the need for further measures to effectively integrate research findings into day-to-day clinical practice. © 2024 The Authors LA - English DB - MTMT ER - TY - JOUR AU - Dragonieri, Silvano AU - Bikov, András TI - Innovating Respiratory Diagnostics: The Game-Changing Role of Biomarkers JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 13 PY - 2024 IS - 19 PG - 2 SN - 2077-0383 DO - 10.3390/jcm13195850 UR - https://m2.mtmt.hu/api/publication/35472722 ID - 35472722 N1 - Export Date: 24 October 2024; Cited By: 0; Correspondence Address: S. Dragonieri; Respiratory Diseases, University of Bari, Bari, 70121, Italy; email: silvano.dragonieri@uniba.it LA - English DB - MTMT ER - TY - JOUR AU - Chai, A. AU - Csoma, Balázs AU - Lázár, Zsófia AU - Bentley, A. AU - Bikov, András TI - The Effect of Opioids and Benzodiazepines on Exacerbation Rate and Overall Survival in Patients with Chronic Obstructive Pulmonary Disease on Long-Term Non-Invasive Ventilation † JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 13 PY - 2024 IS - 18 PG - 11 SN - 2077-0383 DO - 10.3390/jcm13185624 UR - https://m2.mtmt.hu/api/publication/35436011 ID - 35436011 N1 - This article is a revised and expanded version of a conference abstract entitled “Benzodiazepines and Opiates Shorten Exacerbation-Free Time in COPD Patients on Long-Term Non-Invasive Ventilation”, which was presented at the SLEEP 2024 conference, Houston, 1–5 June 2024. AB - Background: There is a growing concern that opioids and benzodiazepines can depress the respiratory drive and could contribute to worsening respiratory failure and higher exacerbation frequency in COPD. However, the relationship between the exacerbation rate and medication taken is poorly understood in patients with chronic respiratory failure due to COPD. Methods: As part of a service evaluation project, we analysed 339 patients with COPD who were established on long-term non-invasive ventilation (LT-NIV) at our tertiary centre. We investigated the relationship between benzodiazepine and opioid prescription and clinical outcomes as well as their impact on the exacerbation rate and overall survival following setup. Results: Before LT-NIV setup, 40 patients took benzodiazepines and 99 patients took opioids. Neither benzodiazepine nor opioid use was associated with changes in daytime blood gases, overnight hypoxia or annual exacerbations before NIV setup, but patients taking opioids were more breathless as assessed by modified Medical Research Council scores (3.91 ± 0.38 vs. 3.65 ± 0.73, p < 0.01). Long-term NIV significantly reduced the number of yearly exacerbations (from 3.0/2.0–5.0/ to 2.8/0.71–4.57/, p < 0.01) in the whole cohort, but the effect was limited in those who took benzodiazepines (from 3.0/2.0–7.0/ to 3.5/1.2–5.5/) or opioids (3.0/2.0–6.0/ to 3.0/0.8–5.5/). Benzodiazepine use was associated with reduced exacerbation-free survival and overall survival (both p < 0.05). However, after adjustment with relevant covariates, the relationship with exacerbation-free survival became insignificant (p = 0.12). Opioids were not associated with adverse outcomes. Conclusions: Benzodiazepines and opiates are commonly taken in this cohort. Whilst they do not seem to contribute to impaired gas exchange pre-setup, they, especially benzodiazepines, may limit the benefits of LT-NIV. © 2024 by the authors. LA - English DB - MTMT ER - TY - JOUR AU - Dragonieri, S. AU - Portacci, A. AU - Quaranta, V.N. AU - Carratu, P. AU - Lazar, Z. AU - Carpagnano, G.E. AU - Bikov, András TI - Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Syndrome Management: A Narrative Review JF - DISEASES J2 - DISEASES VL - 12 PY - 2024 IS - 9 PG - 13 SN - 2079-9721 DO - 10.3390/diseases12090224 UR - https://m2.mtmt.hu/api/publication/35434262 ID - 35434262 N1 - Respiratory Medicine, Dipartimento di Biomedicina Traslazionale e Neuroscienze, University of Bari, Bari, 70121, Italy Internal Medicine “A. Murri”, Department DIMEPREJ, University of Bari, Bari, 70121, Italy Department of Pulmonology, Semmelweis University, Budapest, 1085, Hungary Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, M13 9WL, United Kingdom Export Date: 26 October 2024 Correspondence Address: Dragonieri, S.; Respiratory Medicine, Italy; email: silvano.dragonieri@uniba.it LA - English DB - MTMT ER - TY - JOUR AU - Frent, S. AU - Popovici, A.-F. AU - Balan, A. AU - Cerbu, B. AU - Marincu, I. AU - Mihaicuta, S. AU - Bikov, András TI - Religiosity and Health Outcomes in a Cohort of Romanian Patients Hospitalized for COVID-19 JF - JOURNAL OF RELIGION & HEALTH J2 - J RELIG HEALTH VL - in press PY - 2024 SP - in press SN - 0022-4197 DO - 10.1007/s10943-024-02120-6 UR - https://m2.mtmt.hu/api/publication/35306010 ID - 35306010 N1 - Center for Research and Innovation in Precision Medicine of Respiratory Diseases, Department of Pulmonology, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Sq. No. 2, Timisoara, 300041, Romania Faculty of Psychology and Educational Sciences, University of Bucharest, Panduri Street No. 90, Bucharest, 050657, Romania Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Sq. No. 2, Timisoara, 300041, Romania Infectious Diseases Department, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Sq. No. 2, Timisoara, 300041, Romania Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, M13 9WL, United Kingdom Division of Infection, Immunity & amp; Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, United Kingdom Export Date: 17 September 2024; Cited By: 0; Correspondence Address: A.-F. Popovici; Faculty of Psychology and Educational Sciences, University of Bucharest, Bucharest, Panduri Street No. 90, 050657, Romania; email: filip.popovici@unibuc.ro; CODEN: JRHEA AB - There is a growing body of evidence for the interrelation between health status and religious beliefs. Our aim was to evaluate the level of religiosity in patients hospitalized for COVID-19 and to assess the link between religiosity and measurable health outcomes. This was an observational, single-center study which included patients with moderate-to-severe forms of COVID-19. A total of 112 patients were enrolled in the study, of whom 77 were highly religious (CRS-15 score ≥ 4) and 35 non-highly religious (CRS-15 score < 4). There was no difference in demographics or prevalence of comorbidities between the two groups. Furthermore, we found no difference between groups in radiological extension of lung lesions, length of hospital stays, or ICU need; however, in-hospital mortality rate was significantly lower in highly religious group (1% vs. 14%, p = 0.005). Serum ferritin level at admission was significantly lower (p = 0.03) and prevalence of post-COVID-19 pulmonary sequelae significantly higher in highly religious group (p = 0.02). © The Author(s) 2024. LA - English DB - MTMT ER - TY - JOUR AU - Bikov, András AU - Mihaicuta, S. TI - What has the ESADA Registry Contributed to the Current OSA Knowledge? JF - ARCHIVOS DE BRONCONEUMOLOGIA J2 - ARCH BRONCONEUMOL PY - 2024 SN - 0300-2896 DO - 10.1016/j.arbres.2024.06.002 UR - https://m2.mtmt.hu/api/publication/35070555 ID - 35070555 LA - English DB - MTMT ER - TY - JOUR AU - Bikov, András AU - Bentley, Andrew AU - Csoma, Balázs AU - Smith, Nicola AU - Morris, Bryn AU - Bokhari, Saba TI - Long-Term Adherence to Continuous Positive Airway Pressure in Patients with Obstructive Sleep Apnoea Set Up in a Complete Remote Pathway: A Single-Centre Service Evaluation Project JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 13 PY - 2024 IS - 10 PG - 10 SN - 2077-0383 DO - 10.3390/jcm13102891 UR - https://m2.mtmt.hu/api/publication/34854037 ID - 34854037 AB - Background: Continuous positive airway pressure (CPAP) is the first-line treatment for obstructive sleep apnoea (OSA). Maintaining adherence to CPAP in the long term is a clinical problem, and numerous factors have been identified that impact adherence. Although fully remote diagnostic and CPAP services were frequently utilised during the COVID-19 pandemic for patients with OSA, long-term adherence data have not been published. The aim of this service evaluation project was to describe the long-term adherence to CPAP. We also analysed factors that are associated with it. Methods: two-hundred and eighty patients diagnosed with OSA and set up on CPAP remotely during the first wave of the COVID-19 pandemic as part of routine clinical practice were analysed. Results: One-hundred and seven patients (38%) were fully adherent to CPAP at 24 months, determined by at least 4 h of usage on at least 70% of the days. Of the factors analysed, body mass index, disease severity, driving status and the presence of depression were related to long-term adherence (all p < 0.05). Conclusions: with the likelihood of future pandemics similar to COVID-19, our data provide evidence that fully remote pathways for management of patients with OSA can be designed and be sustainable with good long-term adherence. LA - English DB - MTMT ER - TY - JOUR AU - Schønberg-Moe, A. AU - Csoma, Balázs AU - Bikov, András AU - Müller, Veronika AU - Lázár, Zsófia TI - Platelet count and platelet-to-lymphocyte ratio at the onset of a severe COPD exacerbation are unrelated to the time till the next moderate or severe relapse JF - ADVANCES IN MEDICAL SCIENCES J2 - ADV MED SCI-POLAND VL - 69 PY - 2024 IS - 1 SP - 160 EP - 166 PG - 7 SN - 1896-1126 DO - 10.1016/j.advms.2024.03.003 UR - https://m2.mtmt.hu/api/publication/34771062 ID - 34771062 N1 - Department of Pulmonology, Semmelweis University, 25-29 Tömő Str., Budapest, 1083, Hungary Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, M13 9WL, United Kingdom Division of Infection, Immunity & Respiratory Medicine, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PT, United Kingdom Export Date: 26 October 2024 Correspondence Address: Lázár, Z.; Department of Pulmonology, 25-29 Tömő Street, Hungary; email: lazar.zsofia@med.semmelweis-univ.hu Chemicals/CAS: methylprednisolone, 6923-42-8, 83-43-2; Biomarkers LA - English DB - MTMT ER - TY - JOUR AU - Paróczai, Dóra AU - Burián, Katalin AU - Bikov, András TI - Bacterial Vaccinations in Patients with Chronic Obstructive Pulmonary Disease JF - VACCINES (BASEL) J2 - VACCINES-BASEL VL - 12 PY - 2024 IS - 2 PG - 17 SN - 2076-393X DO - 10.3390/vaccines12020213 UR - https://m2.mtmt.hu/api/publication/34664932 ID - 34664932 AB - Chronic obstructive pulmonary disease (COPD) is a frequent, often progressive, chronic disease of the lungs. Patients with COPD often have impaired immunity; therefore, they are prone to chest infections, such as pneumonia or bronchitis. Acute exacerbations of COPD are major events that accelerate disease progression, contributing to its symptoms’ burden, morbidity, and mortality. Both pneumonia and acute exacerbations in COPD are caused by bacteria against which there are effective vaccinations. Although the number of randomised controlled studies on bacterial vaccinations in COPD is limited, national and international guidelines endorse specific vaccinations in patients with COPD. This review will summarise the different types of vaccinations that prevent pneumonia and COPD exacerbations. We also discuss the results of early phase studies. We will mainly focus on Streptococcus pneumoniae, as this bacterium was predominantly investigated in COPD. However, we also review studies investigating vaccinations against Haemophilus influenzae, Moraxella catarrhalis, and Bordetella pertussis. LA - English DB - MTMT ER -